# Mabworks

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mabworks

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.mab-works.com
- Total disclosed funding: $215M
- Latest round: Series C (Apr 15, 2020)
- Investors on record: 18

## About

Established in 2003 and based in Beijing, China, Mabworks operates as a biopharmaceutical company dedicated to developing antibody drugs. It has more than 50 domestic and foreign invention patents. The chairman of the company, Feng Li graduated from Rice University and has worked in Genentech, Amgen, and Tanox. The CMO of the company, Jinjin Liang graduated from the University of California and has worked in Icon, WuXi Clinical, and IQVIA. In March 2023, Mabworks was listed on the New Third Board. In March 2024, the company raised CNY 217.99 million in strategic investment from new investor CGP Investment and returning investor E-Town International Industrial Investment.

The company focuses on the development of antibodies that stimulate the immune system to deplete target pathogenic cells. It has three technical platforms, including ADCC (antibody-dependent cell-mediated cytotoxicity) enhanced antibody platform, multi-specific antibody platform, and antibody discovery and optimization platform. The ADCC enhanced antibody platform is an antibody glycosylation modification platform, and the company is developing four clinical stage antibody drugs, including MIL62, MIL93, MIL97, and MBS301. Mabworks has developed 8 clinical stage drugs under research. The drugs cover the fields of tumours and autoimmune diseases.

In 2022, the company's revenue was CNY 15.89 million, and its net income was CNY -251.85 million.

## Funding rounds

- Series C, Apr 15, 2020, $160M — BOCOM International Asset Management, China International Capital Corporation, TTGG Ventures, CITIC Securities, Yuexiu Industrial Investment Funds Management, Homsun Capital, Everest VC, E-Town International Industrial Investment, Sealand Innovation, SDIC Unity Capital, CAS Venture Capital, Lyzz Capital, Lake Bleu Capital, Vigintillion Capital, Huge Capital
- Series B, Jan 20, 2017, $39M — GTJA Investment Group, Harvest Fund Management, E-Town International Industrial Investment, MED-FINE Capital
- Series A, May 1, 2016, $15M — GTJA Investment Group, MED-FINE Capital

## Investors

- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series A, Series B
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A, Series B
- Harvest Fund Management — Series B
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series B, Series C
- BOCOM International Asset Management (https://capitalatlas.ai/funds/bocom-international-asset-management) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series C
- CITIC Securities — Series C
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series C
- Homsun Capital (https://capitalatlas.ai/funds/homsun-capital) — Series C
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series C
- Sealand Innovation (https://capitalatlas.ai/funds/sealand-innovation) — Series C
- SDIC Unity Capital (https://capitalatlas.ai/funds/sdic-unity-capital) — Series C
- CAS Venture Capital (https://capitalatlas.ai/funds/cas-venture-capital) — Series C
- Lyzz Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series C
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series C
- Vigintillion Capital — Series C
- Huge Capital (https://capitalatlas.ai/funds/huge-capital) — Series C